The proto-oncogene HER2 is amplified in 20% to 30% of breast cancers, resulting in overexpression of the HER2 protein. HER2+ breast cancer is associated with rapid tumor growth, increased risk of recurrence after surgery, poor response to conventional chemotherapy, and significantly shorter disease-free survival and overall survival than HER2-breast cancer. 1-3 Trastuzumab (Herceptin, Genentech, San Francisco, CA), a humanized monoclonal antibody, has been shown to improve clinical outcomes in the setting of HER2+ metastatic disease or adjuvant treatment for HER2+ invasive breast cancer when used in combination with chemotherapy as a first line. 4 Currently, 2 laboratory methods used to assess HER2 status include immunohistochemical analysis and fluorescence in situ hybridization (FISH), which assess protein overexpression and gene amplification, respectively. Immunohistochemical analysis and FISH are commonly used assays for determining HER2 status because morphologic examination is used to ensure that HER2 analysis is localized within tumor cells. Unfortunately, recent studies have demonstrated less-than-optimal concordance rates between immunohistochemical analysis and FISH among laboratories performing HER2 testing, which has been attributed to lack of standardized testing protocols and test interpretation by inexperienced personnel. [4] [5] [6] A joint American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Task Force recently released guidelines and recommendations intended to improve HER2 testing. 7 The task force introduced guidelines to standardize and improve interlaboratory testing (immunohistochemical analysis and FISH) variability. Specific requirements were established for testing algorithms, specimen handling, fixation requirements, reporting, method validation,
The goal of this study was to assess the performance characteristics of the Automated Cellular Imaging System (ACIS III) for HER2 immunohistochemical analysis. The study was performed on 187 biopsy slides from patients who underwent HER2 testing between January and February 2008. Three scoring methods by the ACIS III were compared with the manual score and fluorescence in situ hybridization (FISH) results for HER2 amplification. The equal distribution score (EQD) method, in which 2 areas each of high-, moderate-, and low-intensity staining were measured, most closely matched the FISH HER2 amplification result. The numbers of immunohistochemically negative (0 or 1+)/ FISH+ cases were equivalent for all methods. The EQD method had significantly fewer 2+ cases (n = 16) (P < .001) vs the manual method (n = 35) and yielded a higher positive predictive value (38%) for HER2 amplification compared with the manual method (20%). The EQD method may more accurately identify FISHamplified HER2 cases with fewer 2+ cases that would be "reflexed" to FISH compared with the manual method.
The proto-oncogene HER2 is amplified in 20% to 30% of breast cancers, resulting in overexpression of the HER2 protein. HER2+ breast cancer is associated with rapid tumor growth, increased risk of recurrence after surgery, poor response to conventional chemotherapy, and significantly shorter disease-free survival and overall survival than HER2-breast cancer. [1] [2] [3] Trastuzumab (Herceptin, Genentech, San Francisco, CA), a humanized monoclonal antibody, has been shown to improve clinical outcomes in the setting of HER2+ metastatic disease or adjuvant treatment for HER2+ invasive breast cancer when used in combination with chemotherapy as a first line. 4 Currently, 2 laboratory methods used to assess HER2 status include immunohistochemical analysis and fluorescence in situ hybridization (FISH), which assess protein overexpression and gene amplification, respectively. Immunohistochemical analysis and FISH are commonly used assays for determining HER2 status because morphologic examination is used to ensure that HER2 analysis is localized within tumor cells. Unfortunately, recent studies have demonstrated less-than-optimal concordance rates between immunohistochemical analysis and FISH among laboratories performing HER2 testing, which has been attributed to lack of standardized testing protocols and test interpretation by inexperienced personnel. [4] [5] [6] A joint American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Task Force recently released guidelines and recommendations intended to improve HER2 testing. 7 The task force introduced guidelines to standardize and improve interlaboratory testing (immunohistochemical analysis and FISH) variability. Specific requirements were established for testing algorithms, specimen handling, fixation requirements, reporting, method validation, quality assurance, and proficiency testing. The task force noted in its report that image analysis (IA) can be an effective tool for achieving consistent interpretation of HER2 expression by immunohistochemical analysis. All IA equipment and procedures must be calibrated and validated within the clinical laboratory. 7 However, there are few data published describing the performance characteristics of IA systems, in comparison with immunohistochemical analysis and FISH, when used in the setting of HER2 testing.
The Automated Cellular Imaging System (ACIS; DAKO, Carpinteria, CA) is an automated IA system that consists of an automated bright-field microscope with proprietary analysis software for analyzing immunohistochemically stained tissue. The ACIS III digitizes an image and then detects, enumerates, and classifies stained cellular objects based on color and shape in areas selected by the operator of the system. The ACIS has been shown in 3 studies to be reliable, rapid, and inexpensive. HER2 results from this imaging system have been shown to correlate more closely to FISH than to manual immunohistochemical interpretation. 6, 8, 9 The goal of this study was to assess the newly released third-generation system (ACIS III) using 3 separate scoring methods and to compare the results of this imaging system with those of manual immunohistochemical scoring and FISH amplification to determine the performance characteristics for HER2 testing on breast cancer specimens.
Materials and Methods

Patient Population
After approval by the Mayo Clinic Institutional Review Board (Rochester, MN), this retrospective study evaluated 187 consecutive slides from patients who underwent routine HER2 testing between January 22, 2008, and February 13, 2008 , at the Mayo Clinic. The testing algorithm for HER2 testing has been previously reported. 10 Briefly, all invasive breast cancers are assessed by HER2 immunohistochemical analysis. Tumors with immunohistochemical scores of 3+ are interpreted as positive and with scores of 0 or 1+ as negative for HER2 protein overexpression. Immunohistochemical HER2 scores of 2+ are interpreted as equivocal and "reflexed" to the Mayo Clinic Cytogenetics Laboratory for FISH HER2 amplification testing.
The data for 159 of 187 patients enrolled in the study were included in the analyses. Of the specimens, 28 were removed from the study as a result of FISH hybridization failure (n = 11), equivocal FISH results (n = 8), or insufficient tissue for FISH analysis (n = 9). The mean and median ages of the 159 patients were 63.9 and 63.0 years, respectively, with a range of 24 to 97 years. The majority of cases (n = 147) were from the breast, with a minority of cases (n = 12) from metastatic breast lesions.
HER2 Immunohistochemical Analysis
All breast cancer specimens evaluated in the study were originally processed using the HercepTest (DAKO), the semiquantitative immunohistochemical assay for determination of HER2 protein (c-erbB-2 oncoprotein) overexpression. Within 1 month of the original clinical diagnosis, all 187 consecutive immunohistochemical HER2 specimens were collected from the clinical files and evaluated using the ACIS III.
The original HER2 immunohistochemical slides were first scanned using the ACIS III instrument, which captured digital images of the immunostained slides. Selection of specific areas within the digitalized image for ACIS III scoring was performed by a cytotechnologist (D.M.M.) trained in IA techniques and breast histomorphologic studies. Three methods were evaluated: the "hot spots only" (HSO), "equal distribution score" (EQD), and "10-region score" (TRS) selection methods ❚Table 1❚. The 40× circle tool on the ACIS III instrument was used for the selection of all areas ( Table 1) .
The HSO method is defined by the technologist selecting 6 areas of invasive breast cancer cells that appeared (by visual examination of the digitized image) to have the most intense cytoplasmic membrane HER2 staining. In the EQD method, 6 areas are also collected, but in contrast with the HSO method, the EQD method evaluates 2 areas of highintensity cytoplasmic membrane HER2 staining, 2 areas of moderate-intensity cytoplasmic membrane HER2 staining, and 2 areas of low-intensity cytoplasmic membrane HER2 staining (2 areas of no staining were substituted when no areas of low staining could be identified). The TRS method consists of a more subjective selection process in which the Hot spots only HSO 6 6 most intensely staining areas Equal distribution EQD 6 2 areas each of high intensity, moderate intensity, and low intensity 10-region score TRS 10 10 areas representing the most common or "average" intensity operator selects 10 areas thought to give the best overall average staining intensity of the entire specimen. After selection of the areas by the technologist, the ACIS III calculates a region score that was then converted to a scoring algorithm consistent with the HercepTest scoring algorithm (ie, 0, 1+, 2+, 3+). Per the manufacturer guidelines, region scores of 0 to 0.49, 0.50 to 1.49, 1.50 to 2.49, and 2.50+ were given immunohistochemical scores of 0, 1+, 2+, and 3+, respectively. The operator of the ACIS III performed all analyses without knowledge of clinicopathologic findings or original HER2 results.
FISH HER2 Analysis
FISH analysis was performed on all cases that were not originally evaluated by FISH as part of routine clinical practice (ie, 2+ immunohistochemical score). For specimens originally scored as 2+ by immunohistochemical analysis and, therefore, had FISH analysis per routine clinical practice, the original FISH results were retrieved and used for statistical purposes. FISH for HER2 amplification was performed in the Mayo Clinic Cytogenetics Laboratory using the PathVysion HER2 DNA probe kit (Abbott Molecular, Abbott Park, IL) as previously described. 4, 11 Briefly, FISH DNA probes were hybridized and analysis performed on pathologist-scribed areas of invasive tumor. In total, 60 nuclei were analyzed by 2 independent technologists. The HER2/centromere 17 ratios were calculated and interpreted according to ASCO/CAP guidelines. 7 
Statistical Analysis
Statistical analysis comparing the number of patients with 2+ immunohistochemistry results based on ACIS III methods was performed with SPSS Windows software, version 11.5 (SPSS, Chicago, IL) using the McNemar test. All tests were 2-tailed, and P values less than .05 were considered significant.
Results
The analyses from the 159 patient specimens are summarized in ❚Table 2❚, ❚Table 3❚, and ❚Table 4❚. The correlations between pathologist manual interpretations and ACIS III HSO, EQD, and TRS methods were 68.6%, 62.3%, and 53.5% of specimens, respectively. However, if the 0 and 1+ scores were considered concordant, which is consistent for consideration of trastuzumab treatment in routine clinical practice, the overall correlations between the manual and HSO, EQD, and TRS ACIS III methods improved to 80.5%, 82.4%, and 84.3%, respectively.
Of 159 specimens, 17 (10.7%) had a positive HER2 FISH result. A summary of the percentage of patients with a positive FISH result based on pathologist manual interpretations or ACIS III scores are shown in ❚Table 5❚. As expected, no specimens with a pathologist or ACIS III score of 0 had a positive FISH result. All 4 scoring methods had 2 falsenegative specimens (ie, 1+ result with a positive FISH result). The false-negative diagnoses were identified in the same 2 cases for each method. The equivocal (2+) results by the pathologist and ACIS III demonstrated some of the most variable results in this study. The EQD and TRS methods had significantly fewer 2+ cases (n = 16 [P < .001] and n = 18 [P = .001], respectively) vs the manual method (n = 35; Table 5 ). Only 12% (4/34) and 20% (7/35) of specimens scored as 2+ using the HSO and pathologist manual methods, respectively, were positive by FISH compared with 33% (6/18) and 38% (6/16) of specimens using the TRS and EQD methods, respectively. All 9 specimens scored as 3+ using the EQD and TRS methods were FISH+, whereas 89% (8/9) and 73% (11/15) of specimens scored as 3+ specimens were positive by FISH with the pathologist manual interpretations and HSO methods, respectively.
Discussion
This study demonstrates that the ACIS III can be a valuable tool for the assessment of HER2 protein overexpression. Prior studies have suggested that a more consistent and accurate method of HER2 analysis would be beneficial to clinical laboratories and patients. 4, [12] [13] [14] [15] [16] [17] The data suggest that one way to improve testing may include automated immunohistochemical analysis. Wang et al 8 first showed that the ACIS had a higher concordance rate and improved sensitivity over manual interpretation compared with FISH testing. Subsequently, Bloom and Harrington 6 also demonstrated that the ACIS had higher interobserver agreement than manual interpretation, further suggesting that IA improves the accuracy and reliability of HER2 immunohistochemical analysis. An additional study assessing IA-immunohistochemical studies concluded that IA (ACIS) HER2 assessment is reliable, rapid, and inexpensive and, similar to the previous 2 studies, correlated highly with the FISH results. 9 However, the major drawback to these studies is the apparent lack of an agreed-on and/or clearly described standard ACIS scoring method.
ChromaVision Medical Systems, which first developed the technology, performed clinical tests using tissue microarrays to prove substantial equivalence to the Food and Drug Administration-approved method, 18 while our study was performed on paraffin-embedded biopsy tissue. Biopsy tissue is typically more heterogeneous than tissue microarrays, introducing a situation in which a significant amount of personal judgment is required in the selection of scorable regions. The ACIS operator's manual states that at least 6 regions should be drawn to produce an overall score. Previous studies, the Food and Drug Administration 510(k) clearance summary, and the ACIS operator's manual have not described a clear method to select these 6 (or more) regions. We attempted to validate the ACIS III by evaluating clearly described scoring methods with the hope that our experience could assist other laboratories in their attempts to implement this technology. Evaluation of 3 ACIS scoring methods was performed in this study. The EQD and TRS methods provided the most accurate results in the 0 and 3+ categories (100%) and increased the percentage of cases that are true-positive in the 2+ category, 38% and 33%, respectively. Furthermore, the EQD method can be easily implemented as a scoring method owing to the reduction in some of the subjectivity of the immunohistochemical HER2 test. By establishing a clear set of IA scoring guidelines that has been validated against an acceptable testing method, laboratories can safely and confidently implement a training regimen that clearly defines the number of regions to score and the staining characteristics of the regions. The results of our study demonstrate that the EQD scoring method would have resulted in 19 fewer cases (11.9%) being sent for FISH without an increase in false-negatives. This finding is beneficial in an increasingly cost-conscious health care environment. Some investigators have surmised that, based on meta-analysis, the lowest cost-effectiveness ratio for HER2 testing is to screen all breast cancer patients with immunohistochemical analysis and to confirm 2+ and 3+ scores with FISH. 19 Our data suggest that FISH testing the 0 and 3+ scores may be unnecessary because there was perfect concordance with the FISH results in these categories.
Researchers have been attempting IA for HER2 quantitation for at least a decade with success. In 2001, Lehr and colleagues 20 reported a study in which they used a G3 Macintosh computer and a standard CCD camera and creative use of the Adobe Photoshop graphics editing application. They were able to show that IA with HER2 immunohistochemical analysis is feasible and yields data that correlate well with semiquantitative estimates of immunostaining intensity and HER2 gene amplification by FISH. Japanese researchers in 2000 were similarly creative in using a color video camera and image processing software in an attempt to quantitate the HER2 immunohistochemical stain. 21 They, too, found significant concordance with the semiquantitative results from microscopic evaluation.
More recently, the medical industry has taken notice of the potential of immunohistochemical quantitation. Technologies competing with the ACIS include Applied Imaging Ariol (Applied Imaging, Newcastle upon Tyne, England), the Aperio ScanScope (Aperio Technologies, Vista, CA), and the Ventana Image Analysis System (VIAS; Ventana Medical Systems, Tucson, AZ). The basic functionality of the Ariol and the Aperio ScanScope seems similar to the ACIS in that both create a digitized image from a glass slide that can then be visualized and regions of interest chosen to be evaluated by the respective proprietary scoring algorithms. Differences emerge when one examines the image capture technology and volume throughput and speed of image capture. The VIAS system operates differently in that the user operates a special optimized microscope and touch-screen controls to identify and capture areas of diagnostic interest that are then calculated by using a scoring algorithm.
A recently published study using the Applied Imaging Ariol system suggests that this imaging system is highly favorable in a cost-benefit analysis. 22 These investigators did not see the large reduction in 2+ cases as we did in the present study. However, they saw a reduction without increasing the false-negative rate, potentially lowering the number of cases reflexed to FISH. Citing the substantial cost of trastuzumab treatments, they claim that preventing as few as 2 unnecessary treatments can result in a digital IA system becoming profitable for a hospital.
The use of the ACIS instrument for HER2 immunohistochemical analysis as a method to determine HER2 protein overexpression is not without limitations. The ACIS instrument relies on an operator analyzing a digitized image that is simply a carefully digitally photographed version of the HER2-stained slide. This image is dependent on a high-quality and consistent HER2 immunohistochemical stain. The ACIS III uses a proprietary color thresholding algorithm for the HER2 analysis that is hard-coded into the purchased package. Therefore, any shift in staining quality has the potential of impacting the score derived by any of the scoring methods described. Up-front cost, time, and space considerations must also be balanced with a laboratory's budget and staffing availability.
Much has been written on the various inadequacies of current HER2 immunohistochemical modalities. The widespread use of IA in immunohistochemical testing in a clinical setting has not been extensively described in the literature. To our knowledge, there are no reports of the assessment of the newest ACIS III using different scoring techniques. In this study, we found that the EQD and TRS methods had equivalent positive predictive values for the detection of FISH+ HER2 cases and had fewer equivocal (2+) HER2 immunohistochemical specimens, which require FISH analysis. The EQD and TRS methods may more accurately identify FISH-amplified HER2 cases with fewer equivocal HER2 immunohistochemical cases that would be reflexed to FISH analysis in comparison with manual interpretation by pathologists. Future prospective studies are needed to determine if the ACIS III can decrease overall costs for patients undergoing HER2 testing while maintaining accurate test results.
